Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance

AbbVie IncTrade
T-Rex 2X Inverse MSTR Daily Target ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? AbbVie Inc trades at $248.69 (market cap $441.94B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.34. The key difference: AbbVie Inc pays a 2.77% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and AbbVie Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

ABBVMSTZ
Market Cap
$441.94B
Sector
HealthLeveraged / Inverse
52-Week High
$263.58$27.92
52-Week Low
$197.38$3.88
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.

Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ trades at $11.27, up 4.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates provided.

The outlook is cautious due to bearish technicals and lack of fundamental data. Risks include market volatility and unverified financial health. Investment opportunity hinges on future earnings clarity and positive analyst coverage, which are currently absent.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.

Read more on MSTZ